Kamada Reports Q1 2026 Results, Reaffirms Strong Annual Guidance Despite Temporary Shipment Delay
KMDA sits 29% above its 52-week low of $6.5 on light trading volume (0.3× avg).
Summary
Kamada reported Q1 2026 financial results, showing modest growth impacted by a temporary shipment delay, but reaffirmed its strong annual guidance for 2026, signaling confidence in future performance.
Key Events · Earnings and Guidance · KMDA
-
Q1 2026 Financial Results
Total revenues were $45.2 million, a 3% increase year-over-year. Net income was $4.1 million, up 4% year-over-year, with diluted EPS at $0.07. Adjusted EBITDA remained flat at $11.6 million.
-
Temporary Shipment Delay Impact
First-quarter results were affected by a temporary shipment delay of a single order, which was subsequently delivered during April, suggesting underlying demand remains strong.
-
2026 Annual Guidance Reaffirmed
Kamada reaffirmed its full-year 2026 guidance, expecting total revenues in the range of $200 million to $205 million and adjusted EBITDA between $50 million and $53 million, representing double-digit organic profitable growth.
-
Strategic Growth Pillars
The company continues to focus on expanding its commercial product portfolio, ramping up plasma collection operations, and evaluating new business development and M&A opportunities.
Analysis · KMDA · Life Sciences
Kamada's first-quarter results showed modest revenue and net income growth, with flat adjusted EBITDA, primarily due to a temporary shipment delay that was resolved in April. Despite this, the company reaffirmed its full-year 2026 guidance for significant revenue and adjusted EBITDA growth, indicating confidence in a stronger performance for the remainder of the year. This update provides investors with the first look at performance against the previously issued annual guidance.
At the time of this filing, KMDA was trading at $8.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $486.3M. The 52-week trading range was $6.50 to $9.35. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.